Merck KGaA, Darmstadt, Germany, Completes Acquisition of the Chemical Business of Mecaro

Merck KGaA, Darmstadt, Germany, announced the closing of the transaction to acquire M Chemicals Inc., the company recently incorporated by Mecaro Co. Ltd. to operate its chemical business.

02 Jan 2023 | Darmstadt, Germany
  • Acquisition is expected to complement a key segment of the Electronics business of Merck KGaA, Darmstadt, Germany, Semiconductor Solutions portfolio
  • With the addition of around 100 new employees as well as state-of-the-art production and R&D facilities in Korea, the company will expand both its regional and global capabilities
  • As part of the “Level Up” growth program of the company’s Electronics business sector, the acquisition will further drive innovation in Semiconductor Solutions, one of the company’s “Big 3” growth engines

Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the closing of the transaction to acquire M Chemicals Inc., the company recently incorporated by Mecaro Co. Ltd. to operate its chemical business. Combining these two businesses is expected to complement a key segment of the company’s Semiconductor Solutions portfolio, while simultaneously building on the company’s localization efforts.

The closing of the transaction followed regulatory clearance and the fulfillment of other customary closing conditions. As a result of the acquisition, the company will gain approximately 100 employees, as well as state-of-the-art production and R&D sites in Korea. The acquisition is part of the “Level Up” growth program of the company’s Electronics business sector, which includes investments of significantly more than € 3 billion from 2021 to 2025 in innovation and capacities, focusing on four, mutually reinforcing key priorities: scale, technology, portfolio, as well as capabilities.

“We’re delighted to announce our recent closing of the acquisition and continue expanding our regional capabilities in Korea, as well as our overall global capacity. The acquisition of M Chemicals Inc. is another milestone in the expansion of our Electronics business and in particular Semiconductor Solutions, one of our “Big 3” growth engines, through targeted smaller to medium-sized acquisitions with high impact,” said Surésh Rajaraman, Senior Vice President and Head of EMD Electronics Thin Film Solutions Business Field.

Downloads

For more information, please contact Chantal Gilsdorf

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to www.emdgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany, generated sales of € 19.7 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

Related News

  1. Press Releases

    MilliporeSigma Launches Single-Use Reactor Designed to Accelerate ADC Manufacturing

    MilliporeSigma launched the first single-use reactor specifically designed to manufacture antibody drug conjugates (ADCs).

    2024/09/10